Head & Neck/Thyroid Cancers
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
Conference Coverage
Metronomic chemotherapy performs well in second-line head and neck cancer
Lower-dose therapy granted PFS and OS gains, with fewer side effects, compared with standard chemotherapy options.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
Conference Coverage
Radiofrequency ablation successful in small thyroid cancers
"Some may prefer to have the cancer completely out, while others are okay with watching and are against any cuts in their neck. This comes as kind...
From the Journals
Study shows higher obesity-related cancer mortality in areas with more fast food
An ecologic study showed a dose-response relationship among measures of food swamp and food desert scores and obesity-related cancer mortality.
Conference Coverage
Expert discusses which diets are best, based on the evidence
The Mediterranean diet is not only helpful for losing weight but also can reduce the risk of various chronic diseases.
From the Journals
Cancer pain declines with cannabis use
Lower use of other meds was also seen in patients who used cannabis.
Feature
Increased cancer in military pilots and ground crew: Pentagon
But military aircrew and ground crew were less likely to die from cancer, compared with the U.S. population.
Feature
EPA seeks to limit ‘forever’ chemicals in U.S. drinking water
The Environmental Protection Agency is proposing a new rule that would greatly limit the concentration of endocrine-disrupting ‘forever’ chemicals...
Feature
‘Infuriating’ prescription denial leaves patient without antiemetics
The patient was experiencing severe side effects from standard chemoradiation with weekly cisplatin.
From the Journals
Docetaxel as alternative to cisplatin for H&N radiotherapy
“This is the first randomized study demonstrating the benefit of an alternate radiosensitizing agent in cisplatin-ineligible patients.”